Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4410206 | 0.95 | ABCC8 (0.47) | ABCC8KCNJ11 | |
| SCHEMBL4410466 | 0.95 | ABCC8 (0.44) | ABCC8KCNJ11 | |
| SCHEMBL4563273 | 0.94 | ABCC8 (0.44) | ABCC8KCNJ11 | |
| SCHEMBL7078790 | 0.84 | ABCC8 (0.44) | ABCC8KCNJ11 | |
| SCHEMBL2344068 | 0.82 | ABCC8 (0.45) | ABCC8KCNJ11 | |
| SCHEMBL6997485 | 0.81 | ABCC8 (0.42) | ABCC8KCNJ11 | |
| SCHEMBL4411989 | 0.81 | ABCC8 (0.38) | ABCC8KCNJ11 | |
| SCHEMBL6802837 | 0.80 | ABCC8 (0.43) | ABCC8KCNJ11 | |
| SCHEMBL4268367 | 0.79 | ABCC8 (0.37) | ABCC8KCNJ11 | |
| SCHEMBL7082470 | 0.78 | ABCC8 (0.38) | ABCC8KCNJ11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340879-A1 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID TRANSFER | CHILDRENS HOSPITAL MED CT (US) | 2025-11-06 | — | — | US | claimed |
| US-12378550-B2 | Compositions and methods for nucleic acid transfer | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2025-08-05 | — | — | US | claimed |
| US-10894960-B2 | Compositions and methods for nucleic acid transfer | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2021-01-19 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| CN-101043891-A | Therapeutic agents targeting the nc ca-atp channel and methods of use thereof | UNIV MARYLAND (US) | 2007-09-26 | — | — | CN | claimed |
| EP-1802313-A2 | THERAPEUTIC AGENTS TRAGETING THE NCCA-ATP CHANNEL AND METHODS OF USE THEREOF | University of Maryland, Baltimore (US) | 2007-07-04 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20030109519-A1 | Use of selective potassium channel openers | NOVO NORDISK (DK) | 2003-06-12 | — | — | US | claimed |
| EP-1140945-B1 | FUSED 1,2,4-THIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK AS (DK) | 2003-06-04 | — | — | EP | claimed |
| US-20020193368-A1 | Use of potassium channel openers for the treatment of insulitis | HANSEN JOHN BONDO (DK) | 2002-12-19 | — | — | US | claimed |
| US-20020086861-A1 | Fused 1,2,4- thiadiazine derivatives, their preparation and use | HANSEN JOHN BONDO (DK) | 2002-07-04 | — | — | US | claimed |
| US-20020035106-A1 | Use of potassium channel agonists for reducing fat food consumption | NOVO NORDISK A/S (DK) | 2002-03-21 | — | — | US | claimed |
| US-20020032193-A1 | Use of potassium channel openers for the treatment of insulitis | NOVO NORDISK A/S (DK) | 2002-03-14 | — | — | US | claimed |
| US-20020028808-A1 | Use of potassium channel agonists for the treatment of cancer | NOVO NORDISK A/S (DK) | 2002-03-07 | — | — | US | claimed |
| CN-1330655-A | Fused 1,2,4-thiadiazine derivatives, their preparation and use | NOVO NORDISK AS (DK) | 2002-01-09 | — | — | CN | claimed |
| WO-2002000665-A1 | USE OF POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF INSULITIS | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | claimed |
| US-6329367-B1 | NERVOUS SYSTEM DISORDERS AND CARDIOVASCULAR DISORDERS | NOVO NORDISK A/S (DK) | 2001-12-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340879-A1 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID TRANSFER | SNRPE, RNASE1, POLRMT | ABCC8 969/4885KCNJ11 3985/4885 |
| US-20030109519-A1 | Use of selective potassium channel openers | KCNJ11, KCNJ2, KCNJ1 | ABCC8 63/4885KCNJ11 1/4885 |
| US-10894960-B2 | Compositions and methods for nucleic acid transfer | SNRPE, RNASE1, POLRMT | ABCC8 969/4885KCNJ11 3985/4885 |
| US-20020086861-A1 | Fused 1,2,4- thiadiazine derivatives, their preparation and use | CYP4F3, TBXAS1, NR3C2 | ABCC8 3610/4885KCNJ11 801/4885 |
| US-12378550-B2 | Compositions and methods for nucleic acid transfer | SNRPE, RNASE1, POLRMT | ABCC8 969/4885KCNJ11 3985/4885 |
| US-20020028808-A1 | Use of potassium channel agonists for the treatment of cancer | KCNN3, KCNN1, KCNN2 | ABCC8 944/4885KCNJ11 7/4885 |
| US-20020035106-A1 | Use of potassium channel agonists for reducing fat food consumption | KCNN3, KCNN2, KCNN1 | ABCC8 985/4885KCNJ11 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.